The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
about
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@ast
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@en
type
label
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@ast
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@en
prefLabel
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@ast
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@en
P2093
P2860
P1476
The PARP Inhibitor Veliparib C ...... f Activity in B-Cell Lymphoma.
@en
P2093
Alice Chen
Alison J Moskowitz
Anas Younes
Andrew D Zelenetz
Ariela Noy
Brian Kiesel
Carol S Portlock
Christine Jarjies
Craig H Moskowitz
P2860
P304
P356
10.1158/1078-0432.CCR-16-3068
P407
P577
2017-03-17T00:00:00Z